Acer Therapeutics Inc. (ACER): Price and Financial Metrics


Acer Therapeutics Inc. (ACER): $2.37

-0.05 (-2.07%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ACER POWR Grades


  • ACER scores best on the Growth dimension, with a Growth rank ahead of 91.43% of US stocks.
  • The strongest trend for ACER is in Momentum, which has been heading down over the past 30 weeks.
  • ACER's current lowest rank is in the Momentum metric (where it is better than 5.04% of US stocks).

ACER Stock Summary

  • ACER has a higher market value than just 4.77% of US stocks; more precisely, its current market capitalization is $34,630,790.
  • The ratio of debt to operating expenses for Acer Therapeutics Inc is higher than it is for about merely 0.4% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ACER comes in at -44.35% -- higher than that of only 6.42% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Acer Therapeutics Inc are DAIO, LCTX, PDEX, CSLT, and EPZM.
  • Visit ACER's SEC page to see the company's official filings. To visit the company's web site, go to www.acertx.com.

ACER Valuation Summary

  • ACER's price/sales ratio is 9.4; this is 147.37% higher than that of the median Healthcare stock.
  • Over the past 188 months, ACER's price/sales ratio has gone NA NA.
  • Over the past 188 months, ACER's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for ACER.

Stock Date P/S P/B P/E EV/EBIT
ACER 2021-08-31 9.4 4.8 -2.2 -0.9
ACER 2021-08-30 9.1 4.7 -2.1 -0.8
ACER 2021-08-27 9.1 4.7 -2.1 -0.8
ACER 2021-08-26 9.2 4.7 -2.2 -0.8
ACER 2021-08-25 9.2 4.7 -2.2 -0.8
ACER 2021-08-24 9.2 4.7 -2.2 -0.8

ACER Growth Metrics

  • The 3 year revenue growth rate now stands at -100%.
  • Its 4 year net income to common stockholders growth rate is now at -143.78%.
  • Its 4 year price growth rate is now at -84.36%.
ACER's revenue has moved up $3,998,133 over the prior 30 months.

The table below shows ACER's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 3.998133 0.915877 -16.90639
2021-03-31 3.998133 -8.952031 -19.44992
2020-12-31 0 -17.02742 -22.88545
2020-09-30 0 -17.13891 -21.80405
2020-06-30 0 -20.0669 -21.12727
2020-03-31 0 -24.82641 -26.39797

ACER Price Target

For more insight on analysts targets of ACER, see our ACER price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.00 Average Broker Recommendation 1.75 (Moderate Buy)

ACER Stock Price Chart Interactive Chart >

Price chart for ACER

ACER Price/Volume Stats

Current price $2.37 52-week high $5.39
Prev. close $2.42 52-week low $2.28
Day low $2.36 Volume 73,000
Day high $2.46 Avg. volume 612,453
50-day MA $2.54 Dividend yield N/A
200-day MA $2.91 Market Cap 33.91M

Acer Therapeutics Inc. (ACER) Company Bio


Acer Therapeutics Inc., formerly Opexa Therapeutics, develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease. It also offers advancing ACER-001 for the treatment of urea cycle disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.


ACER Latest News Stream


Event/Time News Detail
Loading, please wait...

ACER Latest Social Stream


Loading social stream, please wait...

View Full ACER Social Stream

Latest ACER News From Around the Web

Below are the latest news stories about Acer Therapeutics Inc that investors may wish to consider to help them evaluate ACER as an investment opportunity.

Acer Therapeutics Inc. (NASDAQ:ACER): Are Analysts Optimistic?

Acer Therapeutics Inc. ( NASDAQ:ACER ) is possibly approaching a major achievement in its business, so we would like to...

Yahoo | October 9, 2021

FDA Approves NDA for Acer Therapeutics’ ACER-001; Shares Rise

Shares of Acer Therapeutics Inc. (ACER) closed 16.5% higher on Wednesday and then declined 5.51%, at the time of writing, in early trade on Thursday. The stock price moved after the pharmaceutical company and its collaboration partner, Relief Therapeutics Holding SA, received the U.S. Food and Drug Administration’s (FDA) green light to file the New Drug Application (NDA) for ACER-001. ACER-001 (sodium phenylbutyrate) is designed for the treatment of patients with various inborn errors of metabolism, including Urea Cycle Disorders (UCDs) and Maple Syrup Urine Disease (MSUD). The Prescription Drug User Fee Act (PDUFA) target action date of June 5, 2022, has been assigned by the FDA.

Priti Ramgarhia on TipRanks | October 7, 2021

FDA Approves NDA for Acer Therapeutics ACER-001; Shares Rise

Shares of Acer Therapeutics Inc. (ACER) closed 16. The post FDA Approves NDA for Acer Therapeutics ACER-001; Shares Rise appeared first on Smarter Analyst .

Smarter Analyst | October 7, 2021

Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Formulation

Notice of allowance of ACER-001 formulation composition of matter patent application strengthens proprietary position in U.S. until 2036 Notice of allowance of ACER-001 formulation composition of matter patent application strengthens proprietary position in U.S. until 2036

Intrado Digital Media | October 7, 2021

Acer's (ACER) NDA for ACER-001 in UCD Gets FDA Acceptance

The FDA accepts Acer's (ACER) NDA for ACER-001 (sodium phenylbutyrate) for the treatment of patients with urea cycle disorders. A decision is due on Jun 5, 2022. Stock up.

Yahoo | October 7, 2021

Read More 'ACER' Stories Here

ACER Price Returns

1-mo -7.42%
3-mo 2.60%
6-mo -18.28%
1-year -14.75%
3-year -89.61%
5-year -93.34%
YTD -9.54%
2020 -34.66%
2019 -80.07%
2018 45.27%
2017 45.45%
2016 -66.79%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.2198 seconds.